Corbus Pharmaceuticals Holdings, Inc. (CRBP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -106.88M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 90.26M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-106.88M | (m) | (m) | $90.26M | (m) | (m) |
| 2026-03-31 | $-89.84M | (m) | (m) | $74.27M | (m) | (m) |
| 2025-12-31 | $-85.31M | (m) | (m) | $70.09M | (m) | (m) |
| 2025-09-30 | $-75.95M | (m) | (m) | $60.48M | (m) | (m) |
| 2025-06-30 | $-67.04M | (m) | (m) | $50.42M | (m) | (m) |
| 2025-03-31 | $-58.87M | (m) | (m) | $42.10M | (m) | (m) |
| 2024-12-31 | $-48.72M | (m) | (m) | $32.22M | (m) | (m) |
| 2024-09-30 | $-46.22M | (m) | (m) | $30.41M | (m) | (m) |
| 2024-06-30 | $-40.20M | (m) | (m) | $26.16M | (m) | (m) |
| 2024-03-31 | $-37.40M | (m) | (m) | $23.54M | (m) | (m) |
| 2023-12-31 | $-45.08M | (m) | (m) | $31.17M | (m) | (m) |
| 2023-09-30 | $-45.77M | (m) | (m) | $30.43M | (m) | (m) |
| 2023-06-30 | $-44.46M | (m) | (m) | $27.99M | (m) | (m) |
| 2023-03-31 | $-48.62M | (m) | (m) | $26.24M | (m) | (m) |
| 2022-12-31 | $-39.84M | $0.00 | (m) | $16.14M | (m) | (m) |
| 2022-09-30 | $-39.04M | $0.00 | (m) | $15.66M | (m) | (m) |
| 2022-06-30 | $-44.73M | (m) | (m) | $20.25M | (m) | (m) |
| 2022-03-31 | $-49.09M | $233.88K | (m) | $29.01M | (m) | -20990.16% |
| 2021-12-31 | $-55.99M | $881.71K | (m) | $36.45M | (m) | -6350.09% |
| 2021-09-30 | $-66.80M | $1.54M | (m) | $46.79M | (m) | -4338.11% |
| 2021-06-30 | $-86.90M | $2.67M | (m) | $65.62M | (m) | -3250.83% |
| 2021-03-31 | $-108.34M | $2.82M | (m) | $85.04M | (m) | -3837.74% |
| 2020-12-31 | $-122.81M | $3.94M | (m) | $98.27M | (m) | -3119.20% |
| 2020-09-30 | $-129.19M | $5.85M | (m) | $105.64M | (m) | -2207.39% |
| 2020-06-30 | $-120.31M | $7.21M | (m) | $100.27M | (m) | -1668.27% |
| 2020-03-31 | $-80.47M | $36.02M | (m) | $91.77M | (m) | -223.40% |
| 2019-12-31 | $-77.10M | $36.14M | (m) | $89.60M | (m) | -213.33% |
| 2019-09-30 | $-67.51M | $35.50M | (m) | $81.90M | (m) | -190.17% |
| 2019-06-30 | $-57.31M | $34.00M | (m) | $72.55M | (m) | -168.56% |
| 2019-03-31 | $-71.41M | $5.76M | (m) | $60.63M | (m) | -1240.21% |
| 2018-12-31 | $-56.75M | $4.82M | (m) | $48.61M | (m) | -1176.78% |
| 2018-09-30 | $-50.02M | $2.89M | (m) | $41.12M | (m) | -1727.78% |
| 2018-06-30 | $-42.08M | $2.60M | (m) | $33.93M | (m) | -1618.11% |
| 2018-03-31 | $-36.98M | $2.10M | (m) | $29.44M | (m) | -1763.29% |
| 2017-12-31 | $-32.56M | $2.44M | (m) | $26.04M | (m) | -1334.43% |
| 2017-09-30 | $-29.27M | $2.82M | (m) | $23.13M | (m) | -1039.59% |
| 2017-06-30 | $-27.65M | $2.76M | (m) | $21.83M | (m) | -1001.06% |
| 2017-03-31 | $-24.55M | $2.81M | (m) | $19.63M | (m) | -874.14% |
| 2016-12-31 | $-19.99M | $1.91M | (m) | $15.44M | (m) | -1045.56% |
| 2016-09-30 | $-14.91M | $1.90M | (m) | $11.88M | (m) | -784.90% |
| 2016-06-30 | $-11.83M | $1.33M | (m) | $9.20M | (m) | -891.19% |
| 2016-03-31 | $-10.21M | $1.04M | (m) | $7.34M | (m) | -976.63% |
| 2015-12-31 | $-8.85M | $648.38K | (m) | $5.89M | (m) | -1365.51% |
| 2015-09-30 | $-7.61M | (m) | (m) | $4.64M | (m) | (m) |
| 2015-06-30 | $-6.18M | (m) | (m) | $3.45M | (m) | (m) |
| 2015-03-31 | $-4.08M | (m) | (m) | $1.92M | (m) | (m) |
| 2014-12-31 | $-2.65M | (m) | (m) | $1.26M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-557.28K | (m) | (m) | $210.67K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |